BPC-157 human evidence review: what is known, what isn't, and where it stands with the FDA and WADA

The honest answer to "are there human studies on BPC-157?" is: almost none. The evidence base is a large body of rodent and in-vitro research, most of it from Predrag Sikiric's group at the University of Zagreb, and the published human data amount to a small retrospective case series and a two-participant safety pilot. There are no published randomised controlled efficacy trials. BPC-157 is not approved by the FDA or Health Canada, the FDA placed it in Category 2 of its compounding bulk substances list in 2023 over safety concerns, and the World Anti-Doping Agency prohibits it. It is supplied as a research reference standard for laboratory use.

What is BPC-157?

BPC-157 (Body Protection Compound 157) is a pentadecapeptide, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight about 1,419 Da. It was described as a partial sequence of a larger protein isolated from human gastric juice, and it has been synthesised and studied as a standalone peptide since the early 1990s. A fuller primer is in what is BPC-157.

What the rodent and in-vitro evidence reports

The Sikiric group has published well over a hundred papers on BPC-157, with reviews in journals including Current Pharmaceutical Design and Current Neuropharmacology. Across rat and mouse models, the reported effects cluster into a few themes:

• Gastrointestinal protection. The original line of work: reduced lesion severity in models of NSAID, alcohol and stress-induced gastric injury, and in fistula and anastomosis models.
• Soft-tissue healing. Faster functional and histological recovery in transected tendon, ligament and muscle models. Gwyer, Wragg and Wilson reviewed this musculoskeletal literature (Cell and Tissue Research, 2019) and concluded the preclinical results were promising while noting the absence of human trials.
• Angiogenesis and vascular effects. In-vitro work reported increased endothelial cell migration and tube formation, with proposed involvement of VEGFR2 and nitric oxide signalling.
• Cell migration. Tendon fibroblast studies (including work by Chang and colleagues in the early 2010s) reported increased outgrowth and migration, with FAK-paxillin pathway activation proposed as a mechanism.

Rodent studies typically used very low amounts expressed per kilogram of body weight (commonly in the microgram per kg and nanogram per kg range) by intraperitoneal, intragastric or drinking-water routes. How those routes compare is covered in BPC-157 oral vs injectable research.

Limitations of the preclinical evidence

A consistent signal across many papers is meaningful, but several features of this literature limit how far it can be extrapolated:

• Concentration in one group. Most studies come from one laboratory network. Independent replication by unrelated groups is comparatively sparse, and independent replication is the strongest test of a finding.
• Model diversity. Many different injury models are each studied a handful of times, rather than a few models studied exhaustively.
• Mechanism breadth. Effects are reported across almost every organ system. That can indicate a fundamental mechanism, but it also makes specific mechanistic claims harder to pin down.
• Pharmacokinetics. Formal PK work arrived late. He and colleagues (Frontiers in Pharmacology, 2022) characterised BPC-157 in rats and dogs and reported rapid elimination, with a plasma half-life well under an hour, and extensive metabolism to smaller fragments.

BPC-157 human studies: what actually exists

Online claims about BPC-157 in people rely almost entirely on anecdote and on extrapolation from rodent data. Neither replaces a controlled trial, and rodent wound-healing results translate to humans unreliably even for compounds that later succeed.

BPC-157 and the FDA

BPC-157 has never been approved by the FDA. In 2023 the FDA listed it in Category 2 of its interim bulk drug substances list for 503A compounding. Category 2 covers substances the agency considers to present potential significant safety risks; the FDA's stated concerns included possible immunogenicity, peptide-related impurities, and a lack of human safety data. In practice, Category 2 placement means US compounding pharmacies should not compound it. The listing does not by itself say BPC-157 is dangerous; it says the safety case has not been made.

BPC-157 and WADA

For anti-doping purposes, BPC-157 falls under section S0 of the WADA Prohibited List, non-approved substances, prohibited in and out of competition. WADA has named it explicitly as an example in that section since the 2022 list, which removes any ambiguity about whether an unlisted research peptide is covered.

What a credible human trial would need

• Pharmaceutical-grade material with established identity, purity and impurity profiles.
• Formal phase 1 pharmacokinetics and safety in people, including immunogenicity monitoring.
• A randomised, placebo-controlled, blinded design with a defined primary endpoint (for example, a validated tendon function score).
• Registration before enrolment and publication regardless of outcome.

Until that exists, BPC-157 is a research compound with an interesting preclinical profile, not an established therapy.

What this means for laboratory research

The gap between the preclinical signal and the human data is itself a reason the compound remains a research subject. For replication work, the identity and purity of the reference standard matter: a study that cannot rule out a truncated or impure lot cannot attribute its results to BPC-157. Lumera Labs supplies BPC-157 5 mg and 10 mg; the 10 mg lot has a published HPLC-UV certificate at Lab Results, and a COA for the 5 mg is available on request. Related reading: BPC-157 vs TB-500, the BPC-157 reconstitution protocol, and the per-vial charts at /reconstitution/bpc-157-10mg/.

Frequently asked questions